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Introduction 
Adverse reactions to intravascularly administered radiological contrast 
media (CM) may occur immediately on injection or they may be delayed 
by several hours or days after the examination (Panto and Davies, 1986). 
The incidences of these reactions during and after intravenous urography 
(IVU) were investigated at St Luke's Hospital. 
Methodology 
Two surveys were carried out over an ll-week period. In the first survey, 
321 patients (199 males; 122 females) were interviewed to determine the 
presence or absence of a history of exposure to CM, of ailergy and of 
underlying conditions and diseases. The patients were then monitored 
during and after the injection of an ionic CM (UrografinR 60% w/v, 
Schering AG) to determine the time of onset, signs and symptoms and 
severity of immediate adverse reactions, and the treatment given. 
Data for the second survey on delayed adverse reactions were collected by 
means of a questionnaire distributed to 121 patients (42 males; 39 
females) amongst the participants in Survey 1. The questions enquired on 
the presence, the time of onset and the duration of arm pain and rashes, 
and the presence of any other signs and symptoms. The questionnaires 
were to be retuloed one week after the IVU examination. 
A study was also performed to determine the costs that would be involved 
in a changeover from ionic CM to nonionic CM in NU. The information on 
prices and number of patients examined by IVU was obtained from the 
Government Medical Stores and the Department of Radiology 
re~pecti\rely . 
Results 
Survey 1 
1. Incidence of adverse reactions: 35.2% (n=113) experienced a reaction 
that was mild (32.4%, n=104) or moderate (2.8%, n==9) in severity. The 
signs and symptoms which occurred include: heat sensation (n=79), 
nausea (n=40), vomiting (n=l1), retching (n=8), erythema (n=3), 
sneezing (n=3), urticaria (n=2), itching (n=1), arm pain (n=1), coughing 
(n=1), chest pain (n=1), dizziness (n=I), choking sensation (n=1), and 
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nasal congestion (n=l). 82.3% (n=93) of the reactions took place during 
the injection of the CM 
2. Incidence by patient age: The age of the patients ranged from 10-101 
years (mean age = 49.3 years). The highest incidence was in patients 
aged 40-49 years (47.6%) and the lowest incidence was in the 70-79 
year age group (16.7%). 
3. Incidence by history of previous reactions: Reactions occurred in 81.8% 
of patients with a history of reactions and in 24.6% of patients with a 
history of exposure to a CM but not of reactions. 
4. Incidence by history of allergy and underlying conditions: 40% of 
patients with a history of allergy (asthma, hay fever, urticaria, food 
and/or drugs) and 34.5% of patients with no allergies experienced an 
adverse reaction. The highest incidences of reactions were reported 
for thyroid disorders (SO%), anxiety (63.2%), blood dyscrasias (50%), 
respiratory diseases (40%) and renal disease (38.9%). 
5. Incidence by dose of CM: A dose of 1 ml/kg body weight provided the 
lowest incidence of reactions possible (33.3%) at an optimum 
radiodensity. 
6. Effect of pretreatment: Heat sensation was reported by 2 patients out 
of 6 who were pretreated with an .antihistamine or a corticosteroid 
immediately prior to the injection of the CM. 
7. Treatment of adverse reactions: One or more drugs (c1emastine, 
c1emizole, metoc1opramide, hydrocortisone and/or dexamethasone) 
were administered to 14 patients with a mild reaction and to 9 
patients with a moderate reaction for the prophylaxis or symptomatic 
treatment of reactions. 
Survey 2 
66.9% (n=Sl) of the patients returned the questionnaire. 
1. Incidence of delayed adverse reactions: 4S.1 % (n=39) of patients 
reported a delayed reaction. 19.8% (n=16) had arm pain and 18.5% 
(n=15) had a rash. 42.9% of the symptoms reported as free text 
comments were indicative of iodine toxicity (tiredness, constipation, 
abdominal pain, headache). 
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2. Onset and duration of delayed reactions: The time of onset of arm pain 
ranged from 0-3 days after IVU and lasted for 12 hours to 7 days. 
Rashes appeared within 5 hours to 3 days and lasted for 20 minutes to 
2 days. 
3. Relationship between immediate and delayed adverse reactions: 
51.4% of patients with an immediate reaction and 45.7% of patients 
without an immediate reaction experienced a delayed reaction. 
4. Skin reactions: A delayed skin reaction occurred in 31.8% of patients 
with a history of allergy and in 13.8% with a negative history and in 
17.5% of patients without an immediate skin reaction. Delayed 
reactions were more frequent (18.5%, n=15) than immediate reactions 
(1.2%, n=1). 
Cost of ionic and nonionic CM 
Table 1 demonstrates that nonionic CM is 12-17 times more expensive than 
ionic CM. 
Table 1: Cost of ionic and nonionic contrast media at St Luke's Hospital 
Contrast Medium 
Ionic: Diatrizoate 
(Urografin 60% w lv, 
Schering AG) 
Nonionic: Iohexol 
(Omnipaque 300 mg I/ml, 
Nycomed AS) 
Volume of 
Ampoule 
20ml 
10ml 
50ml 
Hospital Price 
(per gram of 
iodine) 
LmO.06,3 
Lm1.08,3 
LmO.80,6 
The cost of CM for an average of 2605 IVU examinations per year and an 
average dose of 63.9 ml per patient was estimated to be LM3,054/year if 
diatrizoate only is administered and Lm43,244/year if iohexol only is 
administered. The cost of prophylactic or symptomatic treatment of 
adverse reactions in 27 patients out of 321 in Survey 1 was Lm3.93,6. 
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Assuming that the same proportion of patients is treated in a year, then 
the annual cost of the drug therapy would be Lm31.92,5. 
Discussion 
Table 2 demonstrates that the incidence of immediate adverse reactions 
to ionic CM in IVU in Malta is high. However, in the studies by Shehadi 
and Toniolo (1980) and Palmer (1988), the sensation of heat was not 
recorded as an adverse reaction. Palmer further stated that mild 
reactions were underreported and nausea and other mild symptoms were 
frequently ignored as mild reactions. Ansell (1987) also noted 
underreporting and inconsistent reporting of adverse reactions. If heat 
sensation were excluded from the Maltese Study, the incidence of adverse 
reactions would be 15.9%. 
Table 2: A comparison of surveys on adverse reactions to ionic contrast 
media 
Study 
Malta (1991)# 
Shehadi & Toniolo (1980)# 
Ansell (1987)# 
Palmer (1988)$ 
Katamaya et al (1990)$ 
Country of 
Origin 
Malta 
N .America, 
Europe, 
Australia 
United Kingdom 
Australia 
Japan 
Note: # surveys on intravenous urography only 
% Incidence of 
Adverse 
Reactions 
35.2% 
4.8% 
8.3% 
3.8% 
12.7% 
$ surveys on all intravascular contrast examinations 
The incidence of delayed adverse reactions to ionic and nonionic 
urographic CM was 30% in a U.K. study (Panto and Davies, 1986). This is 
lower than the 48.1 % incidence in Malta but 29% of the U.K. participants 
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were administered a nonionic CM whereas Maltese patients received 
only an ionic CM. 
Adverse reactions are reduced by a factor of 3-4 when nonionic CM are 
administered instead of ionic CM (Palmer, 1988; Katamaya et aI, 1990). 
However, the universal use of nonionic CM would place a financial 
burden on the State Pharmaceutical Services since the expenditure would 
be 14 times greater than with ionic CM only. 
Conclusion 
The monitoring of patients for immediate and delayed adverse reactions 
is essential in IVU. Drugs and equipment for resuscitation should be 
readily available for the prompt treatment of severe reactions. A 
clinical pharmacist can play a role in providing an information and 
monitoring service for delayed reactions. It is being proposed that a 
record of CM administered to patients should be kept to provide the 
necessary data for the management of delayed reactions and for 
epidemiological purposes. A recommendation is being made for the 
drawing up of a protocol on the use of nonionic CM in high risk patients 
and the pretreatment of patients receiving ionic CM to lower the 
incidence of adverse reactions. 
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